Table II.
ELF5 mRNA expression in epithelial ovarian cancer tissues of clinicopathological indexes.
| Parameters | Total | Positive | Percentage (%) | P-value |
|---|---|---|---|---|
| Age (years) | ||||
| >50 | 27 | 5 | 18.5 | 00.817 |
| ≤50 | 22 | 4 | 18.2 | |
| Pathological staging | ||||
| I–II | 23 | 6 | 26.1 | 0.015 |
| III–IV | 26 | 3 | 11.5 | |
| Pathological grading | ||||
| G1 | 20 | 4 | 20.0 | 0.797 |
| G2 | 17 | 3 | 17.6 | |
| G3 | 12 | 2 | 16.7 | |
| Pathological type | ||||
| Serous cystadenocarcinoma | 32 | 6 | 18.8 | 0.812 |
| Mucinous cystadenocarcinoma | 17 | 3 | 17.6 | |
| Lymphatic metastasis | ||||
| With | 21 | 2 | 9.5 | 0.019 |
| Without | 28 | 7 | 25.0 | |
| Ascites | ||||
| With | 16 | 3 | 18.8 | 0.896 |
| Without | 33 | 6 | 18.2 |
ELF5, E74-like factor 5. Bold indicates that from a total of 49 patients with ovarian cancer, 6 out of 33 patients with no ascites showed ELF5 positive expression.